Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
16 juin 2016 08h00 HE
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™
25 mai 2016 08h00 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 25, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark...
Pernix Therapeutics Announces CEO Transition
11 mai 2016 08h00 HE
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with...